{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:36:48Z","timestamp":1789522608118,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA180822"],"award-info":[{"award-number":["U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA 180868"],"award-info":[{"award-number":["U10CA 180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ygyno.2016.10.036","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T19:34:08Z","timestamp":1477596848000},"page":"96-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology\/Gynecologic Oncology Group study 0231D"],"prefix":"10.1016","volume":"144","author":[{"given":"David M","family":"Hyman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Piekarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred R","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghen E","family":"Tenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martee L","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.10.036_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051372","article-title":"Nationwide surveillance in uterine cancer: survival analysis and the importance of birth cohort: 30-year population-based registry in Taiwan","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0015","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/cncr.27971","article-title":"External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma","volume":"119","author":"Iasonos","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0030","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0035","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0045","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0050","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7","article-title":"Treatment of recurrent or advanced uterine sarcoma - a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase-III trial of the Gynecologic Oncology Group)","volume":"55","author":"Muss","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0060","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase-II trial of ifosfamide and mesna in leiomyosarcoma of the uterus - a Gynecologic Oncology Group-study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0070","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0075","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1302736","article-title":"Characterization of uterine leiomyomas by whole-genome sequencing","volume":"369","author":"Mehine","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"Makinen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0090","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI81534","article-title":"Med12 gain-of-function mutation causes leiomyomas and genomic instability","volume":"125","author":"Mittal","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040015","article-title":"MED12 alterations in both human benign and malignant uterine soft tissue tumors","volume":"7","author":"Perot","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0100","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2009.09.011","article-title":"Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"115","author":"Hensley","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0110","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0115","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0120","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-11-3058","article-title":"A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma","volume":"18","author":"Shan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A - a guardian of poles","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0130","first-page":"60","article-title":"The Aurora kinase family in cell division and cancer","volume":"1786","author":"Vader","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0135","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","article-title":"Dual targeting of mTOR and aurora-A kinase for the treatment of uterine leiomyosarcoma","volume":"18","author":"Brewer Savannah","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","volume":"16","author":"Melichar","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0150","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","article-title":"Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma","volume":"27","author":"Dickson","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0155","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral t-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0160","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2016.10.036_bb0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1053\/j.seminoncol.2015.07.010","article-title":"The National Clinical Trials Network: conducting successful clinical trials of new therapies for rare cancers","volume":"42","author":"Schott","year":"2015","journal-title":"Semin. Oncol."},{"issue":"218","key":"10.1016\/j.ygyno.2016.10.036_bb0180","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.10.036_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA cancer J. Clin."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581631513X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581631513X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T06:51:08Z","timestamp":1536303068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581631513X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S009082581631513X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology\/Gynecologic Oncology Group study 0231D","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}